Trial Profile
A Phase I Clinical Trial of PD-1 Knockout Engineered T Cells Treating Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs PD-1 knockout T-cells (Primary) ; Cyclophosphamide
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- 24 Nov 2020 Status changed from active, no longer recruiting to completed.
- 02 Aug 2019 Planned End Date changed from 30 Jun 2019 to 31 Jan 2020.
- 18 Jan 2019 Planned End Date changed from 1 Dec 2018 to 30 Jun 2019.